Skip to main content
Terug
PODD logo

Insulet Corporation

Datakwaliteit: 100%
PODD
NASDAQ Healthcare Medical - Devices
€ 216,00
▼ € 9,50 (-4,21%)
Marktkapitalisatie: 15,21B
Dagbereik
€ 215,26 € 227,24
52-Weeksbereik
€ 215,26 € 354,88
Volume
1.120.952
50D / 200D Gem.
€ 253,15 / € 297,10
Vorige Slotkoers
€ 225,50

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E 61,5 0,2
P/B 10,0 3,0
ROE % 18,1 3,6
Net Margin % 9,1 3,8
Rev Growth 5Y % 25,3 9,7
D/E 0,7 0,2

Koersdoel Analisten

Hold
€ 357,25 +65.4%
Low: € 286,00 High: € 435,00
Forward K/W
34,09
Forward WPA
€ 6,34
WPA Groei (sch.)
+0,0%
Omzet Sch.
3,31B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 14,53
€ 13,75 – € 14,90
6,14B 5
FY2029 € 12,78
€ 12,10 – € 13,11
5,52B 2
FY2028 € 10,20
€ 9,98 – € 10,70
4,68B 7

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-18 € 1,48 € 1,55 +4,7%
2025-11-06 € 1,14 € 1,24 +8,8%
2025-08-07 € 0,92 € 1,17 +27,2%
2025-05-08 € 0,79 € 1,02 +29,1%
2025-02-20 € 1,00 € 1,15 +15,0%
2024-11-07 € 0,76 € 0,90 +18,4%
2024-08-08 € 0,56 € 0,55 -2,5%
2024-05-09 € 0,39 € 0,73 +87,2%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 25,30% annually over 5 years — strong growth
Earnings declined -40,93% over the past year
ROE of 18,12% — decent returns on equity
Generating 377,70M in free cash flow
P/E of 61,54 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 5,43%

Groei

Revenue Growth (5Y)
25,30%
Revenue (1Y)30,73%
Earnings (1Y)-40,93%
FCF Growth (3Y)132,12%

Kwaliteit

Return on Equity
18,12%
ROIC13,85%
Net Margin9,12%
Op. Margin17,50%

Veiligheid

Debt / Equity
0,69
Current Ratio2,78
Interest Coverage5,94

Waardering

P/E Ratio
61,54
Forward P/E34,09
P/B Ratio10,04
EV/EBITDA32,80
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 30,73% Revenue Growth (3Y) 26,32%
Earnings Growth (1Y) -40,93% Earnings Growth (3Y) 9,44%
Revenue Growth (5Y) 25,30% Earnings Growth (5Y) 95,84%
Profitability
Revenue (TTM) 2,71B Net Income (TTM) 247,10M
ROE 18,12% ROA 7,75%
Gross Margin 71,63% Operating Margin 17,50%
Net Margin 9,12% Free Cash Flow (TTM) 377,70M
ROIC 13,85% FCF Growth (3Y) 132,12%
Safety
Debt / Equity 0,69 Current Ratio 2,78
Interest Coverage 5,94
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 61,54 Forward P/E 34,09
P/B Ratio 10,04 P/S Ratio 5,61
PEG Ratio -1,96 Forward PEG N/A
EV/EBITDA 32,80 Fwd EV/EBITDA 28,53
Forward P/S 4,59 Fwd Earnings Yield 2,93%
FCF Yield 2,48%
Market Cap 15,21B Enterprise Value 15,54B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,71B 2,07B 1,70B 1,31B 1,10B
Net Income 247,10M 418,30M 206,30M 4,60M 16,80M
EPS (Diluted) 3,48 5,78 2,94 0,07 0,25
Gross Profit 1,94B 1,45B 1,16B 805,60M 752,10M
Operating Income 473,80M 308,90M 220,00M 37,60M 126,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3,19B 3,09B 2,59B 2,25B 2,05B
Total Liabilities 1,68B 1,88B 1,86B 1,77B 1,49B
Shareholders' Equity 1,52B 1,21B 732,70M 476,40M 556,30M
Total Debt 1,05B 1,42B 1,45B 1,43B 1,29B
Cash & Equivalents 716,10M 953,40M 650,70M 623,90M 791,60M
Current Assets 1,89B 1,87B 1,57B 1,30B 1,32B
Current Liabilities 680,10M 528,40M 451,20M 364,70M 228,80M